Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE:JNJ) reported positive Phase 3 MonumenTAL-3 results for TALVEY® plus DARZALEX FASPRO® with or without pomalidomide in relapsed/refractory multiple myeloma.
The combinations cut risk of progression or death by up to 72%, showed 24‑month PFS up to 81.3% and OS up to 89.2%, with safety profiles consistent with monotherapies. Johnson & Johnson has submitted an sBLA to the FDA and a Type II variation to the EMA.
Johnson & Johnson (NYSE: JNJ) is expanding U.S. availability of its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The lens addresses cataract-related vision loss and presbyopia in one procedure and is the first and only U.S. FDA‑approved EDOF IOL without a contrast sensitivity loss warning.
According to Johnson & Johnson, more than 500,000 eyes worldwide have received TECNIS PureSee IOL, 97% of patients would recommend it, and 97% reported no very bothersome visual disturbances. A new patient lifestyle quiz supports pre-surgery decision-making during Cataract Awareness Month.
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, a disease with no FDA-approved therapies. The 30 mg/kg group achieved statistically significant durable hemoglobin response and about three times more responders than placebo by 24 weeks.
Mean hemoglobin rose ≥1 g/dL by Week 1, nearly two-thirds met stringent hemoglobin targets by Week 24, fatigue and corticosteroid use improved, safety matched the existing profile, and the sBLA has FDA Priority Review.
Summary not available.
Johnson & Johnson (NYSE: JNJ) entered a definitive agreement to acquire Firefly Bio for $1 billion in cash, adding its proprietary Firelink™ degrader antibody conjugate (DAC) platform.
The deal aims to expand JNJ’s oncology pipeline targeting pan-KRAS and other hard-to-treat solid tumors and to strengthen its next-generation antibody engineering capabilities.
Johnson & Johnson (NYSE: JNJ) reported late-breaking Phase 2 JASMINE data showing nipocalimab met the primary endpoint in adults with moderate-to-severe systemic lupus erythematosus (SLE).
At 24 weeks, more patients on nipocalimab 15 mg/kg plus background therapy achieved an SRI-4 response than placebo. At 52 weeks, higher SRI-4 and LLDAS rates were maintained, especially in autoantibody-positive patients. The safety profile was consistent with prior studies, with no new safety signals. Nipocalimab has FDA Fast Track Designation in SLE and is being further evaluated in the ongoing Phase 3 GARDENIA study.
Johnson & Johnson (NYSE:JNJ) reported new exploratory biomarker analyses from the Phase 2 DAHLIAS study of nipocalimab in adults with moderate-to-severe Sjögren's disease.
Participants with elevated disease-driving autoantibodies and IgG levels achieved 62.5% response on nipocalimab versus 51.9% overall, supporting ongoing Phase 3 DAFFODIL evaluation. Nipocalimab holds FDA Breakthrough and Fast Track designations for this indication but is not yet approved.
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase 1b/2 OrigAMI-4 data for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Confirmed overall response rate was 42%, with 15% complete responses. Median duration of response was not yet reached at 11.8 months. Clinical benefit rate was 63%, median progression-free survival 6.8 months, and overall survival 12.5 months. Safety was mainly Grade 1–2, and an FDA sBLA has been submitted following Breakthrough Therapy Designation.
Johnson & Johnson (NYSE:JNJ) reported final Phase 3 PROTEUS data for investigational perioperative use of ERLEADA (apalutamide) plus hormone therapy in high-risk localized or locally advanced prostate cancer.
The regimen before and after surgery met both primary endpoints, improved multiple disease-control measures, and is not yet approved in this setting.
Johnson & Johnson (NYSE:JNJ) reported updated Phase 1/1b CHRYSALIS-2 data for RYBREVANT plus LAZCLUZE as first-line therapy in atypical EGFR-mutated advanced NSCLC.
Median overall survival reached 41.0 months (~3.5 years), with three- and four-year overall survival rates of 55% and 46%, and a previously reported objective response rate of 57%.
Clinical activity and treatment duration were consistent across multiple atypical EGFR mutation subgroups, and 41% of patients stayed on RYBREVANT for ≥2 years. Safety findings were in line with earlier reports, with mostly Grade 1–2 adverse events and no new safety signals.